Replimune to Present at the William Blair Biotech Focus Conference 2021

Rhea-AI Summary

Replimune Group, Inc. (NASDAQ: REPL) announced that Dr. Robert Coffin, its President and Chief R&D Officer, will speak at the William Blair Biotech Focus Conference 2021. This virtual event is scheduled for July 14, 2021, at 4:20 PM ET, focusing on addressing PD-(L)1 refractory tumors. A webcast will be available on Replimune's website, with a replay accessible for 90 days. Replimune specializes in oncolytic immuno-gene therapies, leveraging its Immulytic® platform to enhance cancer treatment through improved immune responses and viral-mediated tumor cell killing.

WOBURN, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic® platform, today announced that Robert Coffin, Ph.D., President and Chief Research & Development Officer of Replimune, will participate in a panel titled “Novel Mechanisms and Strategies for Addressing PD-(L)1 Refractory/Resistant Tumors” at the William Blair Biotech Focus Conference 2021 taking place virtually on Wednesday, July 14, 2021 at 4:20 PM ET.

A simultaneous webcast will be available in the Investors section of Replimune’s website at www.replimune.com. A replay will be available for approximately 90 days following the conference.

About Replimune
Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 to develop the next generation of oncolytic immune-gene therapies for the treatment of cancer. Replimune is developing novel, proprietary therapeutics intended to improve the direct cancer-killing effects of selective virus replication and the potency of the immune response to the tumor antigens released. Replimune’s Immulytic® platform is designed to maximize systemic immune activation, in particular to tumor neoantigens, through robust viral-mediated immunogenic tumor cell killing and the delivery of optimal combinations of immune-activating proteins to the tumor and draining lymph nodes. The approach is expected to be highly synergistic with immune checkpoint blockade and other approaches to cancer treatment across a broad range of cancers. Replimune intends to progress these therapies rapidly through clinical development in combination with other immuno-oncology products with complementary mechanisms of action as well as in standalone indications. For more information, please visit www.replimune.com.

Investor Inquiries
Chris Brinzey
Westwicke, an ICR Company
339.970.2843
chris.brinzey@westwicke.com

Media Inquiries
Lissette Steele
Verge Scientific Communications
202.930.4762 x 409
lsteele@vergescientific.com

FAQ

What is the focus of Dr. Robert Coffin's presentation at the William Blair Biotech Focus Conference 2021?

Dr. Robert Coffin's presentation will focus on 'Novel Mechanisms and Strategies for Addressing PD-(L)1 Refractory/Resistant Tumors' at the conference.

When will Replimune's presentation take place during the William Blair Biotech Focus Conference 2021?

Replimune's presentation will take place on July 14, 2021, at 4:20 PM ET.

Where can I watch the webcast of the Replimune presentation?

The webcast of the Replimune presentation will be available in the Investors section of their website.

How long will the replay of Replimune's presentation be available?

The replay of Replimune's presentation will be available for approximately 90 days following the conference.

What is the purpose of Replimune's Immulytic® platform?

Replimune's Immulytic® platform aims to enhance systemic immune activation against tumor neoantigens through viral-mediated tumor cell killing.